Altmış beş yaş üstü metastatik yumuşak doku sarkom hastalarında pazopanib tedavisinin etkinliğinin retrospektif değerlendirilmesi
Loading...
Date
2019-02-06
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Bursa Uludağ Üniversitesi
Abstract
Yumuşak doku sarkomları (YDS) mezenşimal hücrelerden köken alan tümörlerin nadir ve heterojen grububudur ve tüm erişkin kanserlerin yaklaşık %1 ini oluşturmaktadır. YDS lerin 50 den fazla farklı histolojik tipi mevcuttur. Pazopanib, Vasküler endotelyal büyüme faktörü reseptör 1 (VEGFR-1), VEGFR-2, VEGFR-3, trombosit kökenli büyüme faktörü a (PDGFR-a) ve c-kit bloke eden oral kullanılan tirozin kinaz inhibitörüdür. İlerlemiş yumuşak doku sarkoması olan yaşlı hastalarda oral multi-tirozin kinaz anjiyogenez inhibitörü pazopanib ile tedavi sonuçlarını geriye dönük olarak inceledik. Medyan yaş 72 (65-79) olan toplam 13 hasta dosyası Ocak 2014-Eylül 2018 arasında retrospektif olarak incelendi. Kapesitabin ve Pazopanib tedavisi kemoterapi sonrasında progrese olan yumuşak doku sarkomlu yaşlı hastalarda etkili ve iyi tolere edilmiştir.
Soft tissue sarcomas (STS) are a rare and heterogeneous group of tumors that originate from mesenchymal cells and account for 1% of all adult malignancies. STS is comprised of more than 50 different histological subtypes. The primary treatments of STS are surgery and radiotherapy. Pazopanib is an oral-used tyrosine kinase inhibitor that blocks vascular endothelial growth factor receptor 1 (VEGFR-1), VEGFR-2, VEGFR-3 platelet-derived growth factor receptor (PDGFR-a), PDGFR-a, and c-kit. We retrospectively reviewed outcomes of treatment with pazopanib, an oral multi-tyrosine kinase angiogenesis inhibitor, in oldest patients with advanced soft tissue sarcoma. A total of 13 patients with a median age of 72 (65-79) were evaluated retrospectively in between January 2014 and September 2018. Pazopanib therapy is effective and well tolerated in oldest patients with STS who had progressive disease after chemotherapy.
Soft tissue sarcomas (STS) are a rare and heterogeneous group of tumors that originate from mesenchymal cells and account for 1% of all adult malignancies. STS is comprised of more than 50 different histological subtypes. The primary treatments of STS are surgery and radiotherapy. Pazopanib is an oral-used tyrosine kinase inhibitor that blocks vascular endothelial growth factor receptor 1 (VEGFR-1), VEGFR-2, VEGFR-3 platelet-derived growth factor receptor (PDGFR-a), PDGFR-a, and c-kit. We retrospectively reviewed outcomes of treatment with pazopanib, an oral multi-tyrosine kinase angiogenesis inhibitor, in oldest patients with advanced soft tissue sarcoma. A total of 13 patients with a median age of 72 (65-79) were evaluated retrospectively in between January 2014 and September 2018. Pazopanib therapy is effective and well tolerated in oldest patients with STS who had progressive disease after chemotherapy.
Description
Keywords
Sarkom, Vasküler endotelyal büyüme faktör reseptör, Anjiyogenez, Sarcoma, Vascular endothelial growth factor receptor, Angiogenesis
Citation
Çubukçu, E. ve Ocak, B. (2019). "Altmış beş yaş üstü metastatik yumuşak doku sarkom hastalarında pazopanib tedavisinin etkinliğinin retrospektif değerlendirilmesi". Uludağ Üniversitesi Tıp Fakültesi Dergisi, 45(1), 83-86.